Regulus RNAi Candidate Can Reduce HCV Treatment To Four Weeks

14 Nov 2016

Although it is on FDA clinical hold to resolve safety concerns about jaundice, RG-101 has shown the ability to significantly reduce the length – and perhaps cost – of HCV therapy when combined with current direct-acting antivirals.

BOSTON – New data on Regulus Therapeutics Inc.’s RNA interference drug RG-101, which had been submitted for presentation at the American Association for the Study of Liver Diseases meeting, show that the Phase II candidate has the efficacy to help it find a commercially viable route into the hepatitis C market, if the company can get past a clinical hold placed by FDA earlier this year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

01 May 2025

• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.